PAVmed/PAVM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About PAVmed

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.

Ticker

PAVM

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Lishan Aklog

Employees

107

Headquarters

New york, United States
Website
pavmed.com

PAVmed Metrics

BasicAdvanced
$14M
Market cap
-
P/E ratio
-$9.08
EPS
0.73
Beta
-
Dividend rate
$14M
0.72638
$7.75
$1.38
57K
0.538
0.53
-8.32%
-147.38%
4.534
375.71%
38.97%

What the Analysts think about PAVmed

Analyst Ratings

Majority rating from 4 analysts.
Buy

PAVmed Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,520.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
0.00%
Net income
-$15M
8.57%
Profit margin
-1,520.00%
8.57%

PAVmed Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 56.57%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.10
-$2.40
-$1.81
-$2.62
-
Expected
-$2.85
-$2.05
-$1.89
-$1.67
-$1.45
Surprise
-26.32%
17.07%
-4.23%
56.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for PAVmed stock?

PAVmed (PAVM) has a market cap of $14M as of June 17, 2024.

What is the P/E ratio for PAVmed stock?

The price to earnings (P/E) ratio for PAVmed (PAVM) stock is 0 as of June 17, 2024.

Does PAVmed stock pay dividends?

No, PAVmed (PAVM) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next PAVmed dividend payment date?

PAVmed (PAVM) stock does not pay dividends to its shareholders.

What is the beta indicator for PAVmed?

PAVmed (PAVM) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the PAVmed stock price target?

The target price for PAVmed (PAVM) stock is $10.75, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell PAVmed stock

Buy or sell PAVmed stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing